ArticleCureus2026
Seizure As the Sentinel Event: An Atypical Presentation of Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis in a Young Adult Male.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report details an atypical presentation of anti-N-methyl-D-aspartate (NMDA) receptor encephalitis in a 21-year-old male, characterized by a "seizure-first" phenotype. The patient's initial generalized tonic-clonic seizure led to a misdiagnosis of epilepsy, and subsequent psychiatric symptoms were incorrectly attributed to the side effects of antiepileptic medication or a new, undiagnosed psychiatric disorder. This resulted in an involuntary psychiatric admission and a delay in diagnosis and, thus, definitive treatment. Once the Graus criteria for probable anti-NMDA receptor encephalitis were met (presence of at least four out of six neuropsychiatric symptom categories, an abnormal electroencephalogram (EEG), and the reasonable exclusion of alternative causes), the patient was empirically treated with high-dose steroids. Upon detecting anti-NMDA receptor antibodies at a serum titer of 1:1000 and a cerebrospinal fluid (CSF) titer of 1:100, the treatment regimen was escalated to include plasmapheresis. In this patient's case, earlier consideration of autoimmune encephalitis during his initial presentation of new-onset seizures and rapid psychiatric decline could have prevented the diagnostic delay and involuntary psychiatric admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.